Biocare Lifesciences Inc (BLI), a Philippines based pharmaceutical company who brought the brands of Remdesivir and Favipiravir in the country last year, announced the launched of the first branded generic of Tocilizumab (Temziva) 400mg/20mL Solution for infusion.

Temziva (Tocilizumab), a treatment known as an Interleukin-6 (IL-6) receptor blocker, has received approval from the Philippines Food and Drug Administration (FDA) to treat severe Covid-19 patients with Cytokine Release Syndrome.

Tocilizumab is an Interleukin-6 (IL-6) receptor blocker that can effectively block what is known as the IL-6 signal transduction pathway, which plays an important role in Cytokine Release Syndrome.

“The availability of tocilizumab in the Philippines is another milestone in the fight against Coid-19,” said Dileep Tiwari, managing director. “As a healthcare company, it is our responsibility to make available products of the highest standards and quality to address high unmet needs among our patients.”

SRS Life Sciences, a global company headquartered in Singapore and focused on lessening disease burden across emerging nations, AryoGen, a biopharmaceutical production company that aims to increase the availability of biopharmaceutical products to improve patients’ quality of life.